论文部分内容阅读
目的探讨前列地尔联合替米沙坦治疗早期糖尿病肾病的临床疗效。方法收集2014年1月至2015年1月在我院就诊治疗的86例早期糖尿病肾病患者资料,运用随机双盲法进行分组,对照组43例患者应用替米沙坦进行治疗,观察组43例患者在对照组基础上应用前列地尔进行治疗,比较两组患者的生化指标。结果两组患者治疗前生化指标比较,差异无统计学意义(P>0.05);经治疗后,观察组患者的尿微量清蛋白、24 h尿蛋白、血尿素氮、血肌酐下降程度明显优于对照组,差异均有统计学意义(均P<0.05)。结论前列地尔与替米沙坦联合治疗早期糖尿病肾病的效果更为突出。
Objective To investigate the clinical efficacy of alprostadil plus telmisartan in the treatment of early diabetic nephropathy. Methods The data of 86 patients with early diabetic nephropathy treated in our hospital from January 2014 to January 2015 were collected and randomly divided into two groups. In the control group, 43 patients were treated with telmisartan, and 43 patients in the observation group The patients were treated with alprostadil on the basis of the control group, and the biochemical indexes were compared between the two groups. Results Before treatment, there was no significant difference in biochemical parameters between the two groups (P> 0.05). After treatment, the levels of urinary albuminuria, 24 h urine protein, blood urea nitrogen and serum creatinine in the observation group were significantly better than those in the observation group Control group, the differences were statistically significant (P <0.05). Conclusion Alprostadil and telmisartan combined treatment of early diabetic nephropathy effect is more prominent.